Cited by 608Dementia and Cognitive Impairment ResearchMedical Imaging Techniques and ApplicationsAlzheimer's disease research and treatments

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R. +3 more·2007·Brain

Abstract

Distinguishing Alzheimer's disease (AD) and frontotemporal dementia (FTD) currently relies on a clinical history and examination, but positron emission tomography with [(18)F] fluorodeoxyglucose (FDG-PET) shows different patterns of hypometabolism in these disorders that might aid differential diagnosis. Six dementia experts with variable FDG-PET experience made independent, forced choice, diagnostic decisions in 45 patients with pathologically confirmed AD (n = 31) or FTD (n = 14) using five separate methods: (1) review of clinical summaries, (2) a diagnostic checklist alone, (3) summary and checklist, (4) transaxial FDG-PET scans and (5) FDG-PET stereotactic surface projection (SSP) metabolic and statistical maps. In addition, we evaluated the effect of the sequential review of a clinical summary followed by SSP. Visual interpretation of SSP images was superior to clinical assessment and had the best inter-rater reliability (mean kappa = 0.78) and diagnostic accuracy (89.6%). It also had the highest specificity (97.6%) and sensitivity (86%), and positive likelihood ratio for FTD (36.5). The addition of FDG-PET to clinical summaries increased diagnostic accuracy and confidence for both AD and FTD. It was particularly helpful when raters were uncertain in their clinical diagnosis. Visual interpretation of FDG-PET after brief training is more reliable and accurate in distinguishing FTD from AD than clinical methods alone. FDG-PET adds important information that appropriately increases diagnostic confidence, even among experienced dementia specialists.

Integrity signals

Registry

Crossref · 10.1093/brain/awm177

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • FDG-PET has significant diagnostic accuracy for differential diagnosis between AD and FTD with high specificity (>95%) in multiple studies.

    “FDG-PET has significant diagnostic accuracy for the differential diagnosis between AD and FTD with high specificity (>95%) in multiple studies [129–131].”
  • FDG-PET imaging shows hypometabolism in Alzheimer's disease brains, mainly in the temporoparietal cortex including the precuneus and posterior cingulate cortex.

    “[18F] fluorodeoxyglucose (FDG)-PET imaging showed hypometabolism in AD brains, mainly in the temporoparietal cortex including the precuneus and posterior cingulate cortex (Reiman et al., 1996; Foster et al., 2007).”

    From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Foster et al., 2007

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., & Minoshima, S.
Affiliations
  • University of Utah (US)
  • University of Washington (US)
Venue
Brain
Published
2007-10-01
Volume
130
Issue
10
Pages
2616-2635
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2026553142
Cited by
608
References
6
Citations by year
2026: 16 · 2025: 22 · 2024: 19 · 2023: 18 · 2022: 19 · 2021: 31 · 2020: 39 · 2019: 29 · 2018: 33 · 2017: 30 · 2016: 31 · 2015: 38 · 2014: 36 · 2013: 42 · 2012: 34
FWCI
25.84
Type
journal article
Language
en
Open access
closed
Locations
  • Brain (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Pennsylvania
  • National Alzheimer's Coordinating Center
  • National Institutes of Health (AG 10 124, AG10129)
  • National Institute on Aging (P30AG010129, AG 08671, U01AG016976, P30AG010124, AG-10124, AG-10129, AG-16976, P50AG008671)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
frontotemporal dementia, Alzheimer's disease, FDG-PET, differential diagnosis, brain hypometabolism, diagnostic accuracy, inter-rater reliability
MeSH terms
Adult, Aged, Alzheimer Disease, Brain, Dementia, Diagnosis, Differential, Female, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Sensitivity and Specificity, Observer Variation, Disease Progression, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review